The firm enjoys a massive 68.7 per cent market share in the
respiratory inhalation segment in India and has started working on aligning
supplies so that there is no shortage of these critical medicine.
Cipla, the market
leader in respiratory therapies, expects a surge in demand for respiratory
drugs and inhalers during the coming months when the winter and an anticipated
second Covid wave are likely to push up demand for these medicines.
The firm enjoys a
massive 68.7 per cent market share in the respiratory inhalation segment in
India and has started working on aligning supplies so that there is no shortage
of these critical medicines.
During this time,
pollution levels (especially in north India) and other environmental factors
cause a surge in respiratory illnesses. Cipla
aspires to become the global lungs leader and it currently ranks second in the
world.
People, who are
recovering from Covid-19,
are also suffering from lung damage and other respiratory illnesses as an
after-effect of the illness.
A recent study of
55 people recovering from Covid in China shows that even after three months of
leaving the hospital, about 70 per cent of those in the study continued to have
abnormal lung scans. The findings in EClinicalMedicine came from a team in
Henan province of China led by Aiguo Xu of the first affiliated hospital of
Zhengzhou University; Yanfeng Gao, Zhengzhou University; and Hong Luo, Guangshan
People’s Hospital.
Speaking to
Business Standard, Cipla global chief financial officer (CFO) Kedar Upadhye
said the company’s respiratory portfolio, including inhalers and oral drugs,
was significant.
No comments:
Post a Comment